2.2021 Asian Pacific Society of Cardiology Consensus Recommendations on the use of P2Y12 receptor antagonists in the Asia-Pacific Region: Special populations.
W E I C H I E H T A N TAN ; P C H E W CHEW ; L A M T S U I TSUI ; T A N TAN ; D U P L Y A K O V DUPLYAKOV ; H A M M O U D E H HAMMOUDEH ; Bo ZHANG ; Yi LI ; Kai XU ; J O N G ONG ; Doni FIRMAN ; G A M R A GAMRA ; A L M A H M E E D ALMAHMEED ; D A L A L DALAL ; T A N TAN ; S T E G STEG ; N N G U Y E N NGUYEN ; A K O AKO ; A L S U W A I D I SUWAIDI ; C H A N CHAN ; S O B H Y SOBHY ; S H E H A B SHEHAB ; B U D D H A R I BUDDHARI ; Zu Lv WANG ; Y E A N Y I P F O N G FONG ; K A R A D A G KARADAG ; K I M KIM ; B A B E R BABER ; T A N G C H I N CHIN ; Ya Ling HAN
Chinese Journal of Cardiology 2023;51(1):19-31
6.The application of the non-woven fabric and filter paper "sandwich" fixation method in preventing the separation of the mucosal layer and muscular layer in mouse colon histopathological sections.
L SHEN ; Y T LI ; M Y XU ; G Y LIU ; X W ZHANG ; Y CHENG ; G Q ZHU ; M ZHANG ; L WANG ; X F ZHANG ; L G ZUO ; Z J GENG ; J LI ; Y Y WANG ; X SONG
Chinese Journal of Pathology 2023;52(10):1040-1043
8.Pulmonary anaplastic lymphoma kinase positive histiocytosis: report of a case.
W M XU ; Z R GAO ; X LI ; Y JIANG ; Q FENG ; L W RUAN ; Y Y WANG
Chinese Journal of Pathology 2023;52(11):1168-1170
10.Clinicopathological and molecular genetic characteristics of ELOC mutated renal cell carcinoma.
Z WEN ; W H ZHANG ; J Y LIANG ; J CHAI ; Y M WANG ; W N XU ; Z WANG ; L N FAN
Chinese Journal of Pathology 2023;52(12):1204-1209
Objective: To investigate the clinicopathological features, molecular genetic features, differential diagnosis and prognosis of ELOC mutated renal cell carcinoma. Methods: From January 2015 to June 2022, 11 cases of renal cell carcinoma with clear-cell morphology, expression of CAⅨ and CK7 and no 3p deletion were collected. Two cases of ELOC mutant renal cell carcinoma were diagnosed using whole exome sequencing (WES). The clinical features, morphology, immunophenotype, FISH and WES results were analyzed. The relevant literature was reviewed. Results: The two patients were both male, aged 29 and 51 years, respectively. They were both found to have a renal mass by physical examination. The maximum diameters of the tumors were 3.5 cm and 2.0 cm, respectively. At the low magnification, the tumors were well-defined. The tumor cells showed a pushing border and were separated by thick fibrous bands, forming nodules. The tumor cells were arranged in a variety of patterns, including tubular, papillary, solid nest or alveolar. At high magnification, the tumor cells were large, with well-defined cell borders and clear cytoplasm or fine eosinophilic granules. CAⅨ was diffusely box-like positive in both cases. Case 1 was partially and moderately positive for CK7, strongly positive for CD10, diffusely and moderately positive for P504S, and weakly positive for 34βE12. In case 2, CK7 and CD10 were both partially, moderately positive and P504s were diffusely positive, but 34βE12 was negative. FISH results showed that both cases had no 3p deletion. ELOC c.235T>A (p.Y79N) mutation was identified using WES in case 1, while ELOC c.236_237inv (p.Y79C) mutation was identified in case 2. Conclusions: As a new clinical entity, ELOC mutated renal cell carcinoma may be underdiagnosed due to its overlap with clear cell renal cell carcinoma in morphology and immunophenotype. The diagnosis of renal cell carcinoma with ELOC mutation should be confirmed by morphology, immunohistochemistry, FISH and gene mutation detection. However, more additional cases are needed to explain its biological behavior and prognosis.
Humans
;
Male
;
Biomarkers, Tumor/genetics*
;
Carcinoma, Renal Cell/pathology*
;
Chromosome Aberrations
;
Kidney Neoplasms/pathology*
;
Molecular Biology
;
Mutation
;
Prognosis
Result Analysis
Print
Save
E-mail